RJA
SILK

Raymond James & Associates’s Silk Road Medical, Inc. Common Stock SILK Stock Holding History

Raymond James & Associates’s Portfolio SILK Stock Details SILK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29,955
Closed -$449K – 3973
2023
Q3 		$449K Sell
29,955
-1,229
-4% -$25.6K ﹤0.01% 2965
2023
Q2 		$1.01M Buy
31,184
+1,042
+3% +$38.1K ﹤0.01% 2462
2023
Q1 		$1.18M Sell
30,142
-2,295
-7% -$112K ﹤0.01% 2362
2022
Q4 		$1.71M Buy
32,437
+14,332
+79% +$698K ﹤0.01% 2091
2022
Q3 		$815K Buy
18,105
+1,254
+7% +$53.9K ﹤0.01% 2525
2022
Q2 		$613K Sell
16,851
-821
-5% -$29.8K ﹤0.01% 2784
2022
Q1 		$730K Buy
17,672
+3,304
+23% +$116K ﹤0.01% 2815
2021
Q4 		$612K Sell
14,368
-1,040
-7% -$52K ﹤0.01% 2942
2021
Q3 		$848K Buy
15,408
+293
+2% +$15.3K ﹤0.01% 2694
2021
Q2 		$723K Sell
15,115
-591
-4% -$30.1K ﹤0.01% 2816
2021
Q1 		$796K Buy
+15,706
New +$873K ﹤0.01% 2662

Other funds holding SILK

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Raymond James & Associates's SILK Position: Q4 2023 in Review

Raymond James & Associates sold out of Silk Road Medical, Inc. Common Stock (SILK) in Q4 2023, closing a stake of 29,955 shares — an estimated $449K sold.

Raymond James & Associates first reported a position in SILK in Q1 2021 and held it in 11 quarters. The position peaked at $1.71M in Q4 2022. 133 funds tracked by Wall St. Rank hold SILK as of Q4 2023.

  • Raymond James & Associates reported no remaining Silk Road Medical, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 29,955 Silk Road Medical, Inc. Common Stock shares in Q4 2023, an estimated $449K.
  • Raymond James & Associates first reported a position in Silk Road Medical, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
  • Raymond James & Associates's Silk Road Medical, Inc. Common Stock position peaked at $1.71M in Q4 2022.
  • 133 funds tracked by Wall St. Rank held Silk Road Medical, Inc. Common Stock as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.